The Connected Clinician: Top Stories of the Week for November 25

High Incidence of PTSD Among Cancer Patients

Ingrezza Improves TD Symptoms In Year-long Extension

HIV Patients Face Increased Risk of Cardiovascular, Kidney Disease Interaction

DAAs Stay Effective For HCV/HIV Co-infection

Prolonged Concussion Symptoms Identifiable by Salivary MicroRNA

Common Malaria Drug Prevents Zika Pregnancy Transmission

FDA Approves First Two-Drug Regimen for HIV

FDA Grants Lofexidine Priority Review for Opioid Withdrawal Treatment

Antibody Analysis Could Lead to Strengthened Malaria Vaccine

FDA Approves Azure Pacemaker Line

News doesn't stop for the holiday season. That much is evident this week, as MD Magazine cruised into the long Thanksgiving weekend with a docket of breaking news and coverage of major studies. Before making a leftover turkey sandwich or gearing up for Cyber Monday, check out what you may have missed with the Connected Clinician Top Stories of the Week!33% of patients that were diagnosed with PTSD were still experiencing persistent symptoms - in many cases worsening - at 4-year follow-up.In 2 different dose groups, patients reported gradual decreases in AIMS scores over 42 weeks.Patients with HIV are at risk of CVD and CKD, and the likelihood increases significantly as risk levels rise.Patients co-infected with Hepatitis C and HIV reported similar sustained virologic responses to those of solely HCV-infected patients.5 microRNAs could successfully confirm PCS with 85% accuracy, outperforming the standard patient survey measures of symptom burden.Chloroquine could serve as an endemic response to Zika in lieu of a vaccination.Juluca is the first complete treatment regimen containing only 2-drugs, instead of 3 or more in standard treatment.This would be the first and only non-opioid, non-addictive medication for management of opioid withdrawal.Researchers continue to seek means to improve the efficacy and tolerability of the RTS,S vaccine. Medtronic’s Azure XT MRI and Azure S MRI pacemakers improved longevity by 27% compared to available predecessors.